This study builds, in part, upon preliminary results generated as part of the
Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this
investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1)
on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and
aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The
investigators hypothesize that participants who carry alleles that modify the activity or
expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore